Research Article
BibTex RIS Cite

Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease

Year 1993, Volume: 6 Issue: 4, 131 - 136, 01.12.1993

Abstract

Intensive clinical investigations on Somatostatin have been being carried out in recent years. Somatostatin and its synthetic analogues were initially used in the treatment of endocrine tumors. Today, they are being studied in the treatment of gastrointestinal diseases and successful results are being obtained.

20 chronic liver disease (CLD) patients (10 chronic active hepatitis (CAH) and 10 cirrhosis), and 10 controls were included in this study. Effects of Octreotide on portal venous flow velocity were investigated using Pulsed Doppler technique. All the patients were given 100 meg Octreotide (SC), after the determination of baseline values of blood pressure; pulse rate; blood glucose, urea, creatinin, Na, K and portal venous flow velocity. These criteria were determined again in the 15, 30, 45, 60, 120 and 180th minutes after the injection.

In the patients with CAH, portal venous flow velocity was changed from 11.8+2.6 cm/sec. to 9.9+2.5 cm/sec. in the 15th min. (p<0.01); to 8.7+1.9

cm/sec. in the 30th min. (p<0.01); to 8.6+2.1

cm/sec. in the 45th min. (p<0.01); to 8.7+2.0

cm/sec. in the 60th min. (p<0.01); to 9.0+2.2

cm/sec. in the 120th min. (p<0.05); and to 9.1+2.3 cm/sec. in the180th min. (p<0.05). In the cirrhotic patients and in controls, portal venous flow velocity showed similar changes and we observed that the efficacy of the drug continued until the 180 th minute.

The results of this study revealed that Octreotide had caused reduction in portal venous flow velocity with a rate of 30-35 % in controls, and 20-25 % in patients with CLD.

References

  • Kurtz K. riuesch E.Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21 (Suppl 119) : 65 - 72.
Year 1993, Volume: 6 Issue: 4, 131 - 136, 01.12.1993

Abstract

References

  • Kurtz K. riuesch E.Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21 (Suppl 119) : 65 - 72.
There are 1 citations in total.

Details

Subjects Clinical Sciences
Journal Section Review Makaleler
Authors

S. Hülagü This is me

İ. Dinç This is me

M. Altın This is me

M. Danacı This is me

M. Özel This is me

Z. Çankır This is me

G. Öztürk This is me

M. Yaylacı This is me

N. Üskent This is me

S. Yürütken This is me

Publication Date December 1, 1993
Published in Issue Year 1993 Volume: 6 Issue: 4

Cite

APA Hülagü, S., Dinç, İ., Altın, M., Danacı, M., et al. (1993). Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Medical Journal, 6(4), 131-136.
AMA Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S. Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Med J. December 1993;6(4):131-136.
Chicago Hülagü, S., İ. Dinç, M. Altın, M. Danacı, M. Özel, Z. Çankır, G. Öztürk, M. Yaylacı, N. Üskent, and S. Yürütken. “Evaluation of the Effects of Octreotide on Portal Hemodynamics Using Pulsed Doppler Ultrasonography in Patients With Chronic Liver Disease”. Marmara Medical Journal 6, no. 4 (December 1993): 131-36.
EndNote Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S (December 1, 1993) Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Medical Journal 6 4 131–136.
IEEE S. Hülagü, “Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease”, Marmara Med J, vol. 6, no. 4, pp. 131–136, 1993.
ISNAD Hülagü, S. et al. “Evaluation of the Effects of Octreotide on Portal Hemodynamics Using Pulsed Doppler Ultrasonography in Patients With Chronic Liver Disease”. Marmara Medical Journal 6/4 (December 1993), 131-136.
JAMA Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S. Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Med J. 1993;6:131–136.
MLA Hülagü, S. et al. “Evaluation of the Effects of Octreotide on Portal Hemodynamics Using Pulsed Doppler Ultrasonography in Patients With Chronic Liver Disease”. Marmara Medical Journal, vol. 6, no. 4, 1993, pp. 131-6.
Vancouver Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S. Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Med J. 1993;6(4):131-6.